COMPANY

Management Team

Company Management


  • Brent Norton, MD,
    Acting Chief Executive Officer

    Dr. Norton is a leader in the Life Science industry with operational and Director experience across several successful enterprises which achieved significant multiples for investors. Dr. Norton founded PreMD, completing IPO's and listings on both TSX and AMEX. Operationally, he has built R&D and commercial operations, led transactions with AstraZeneca, Atherogenics, Eli Lilly, L'Oreal, Parke Davis/Pfizer, etc., and taken products through the FDA to global out-licensing with Johnson & Johnson. He is a founding Director of Novadaq Technologies (TSX:NDQ, NASDAQ:NVDQ), one of Canada's most valuable medical companies. Dr. Norton has been an active member of several BOD's, public and private, in both Canada and the US. He is a Venture Partner at Lumira Capital, a member of the Research Committee for CAMH, an Advisory BOD member for the Ivey International Centre for Health Innovation, and a Past-President and Director of the Osler Bluff Ski Club and Director of Alpine Ontario.


  • Jo-Anne Piché,
    Chief Financial Officer

    With more than 20 years of experience and for the past 12 years being an assurance senior manager for two Canadian large firms, Jo-Anne's assisted entities with successfully planning and executing significant corporate milestones such as IPOs, reverse take-overs, mergers and acquisitions, assurance engagements, as well as strategic planning. Jo-Anne has developed additional experience in financing, corporate restructuring, due diligence, internal controls, business valuations and financial reporting and the elaboration of business plans. Jo-Anne was designated a CPA Auditor, CGA, after having completed a Bachelor in Accounting from Université du Québec à Montréal.


  • Jeff Skinner,
    VP Business Development

    Jeff has fifteen years experience with healthcare organizations, specifically in Business Development, and brings a long deal sheet having completed a wide range of deal types in Specialty Pharma, Biotech and Generic licensing agreements.

Board of Directors


  • Brent Norton, MD,
    Executive Chairman of the Board

    Dr. Norton is a leader in the Life Science industry with operational and Director experience across several successful enterprises which achieved significant multiples for investors. Dr. Norton founded PreMD, completing IPO's and listings on both TSX and AMEX. Operationally, he has built R&D and commercial operations, led transactions with AstraZeneca, Atherogenics, Eli Lilly, L'Oreal, Parke Davis/Pfizer, etc., and taken products through the FDA to global out-licensing with Johnson & Johnson. He is a founding Director of Novadaq Technologies (TSX:NDQ, NASDAQ:NVDQ), one of Canada's most valuable medical companies. Dr. Norton has been an active member of several BOD's, public and private, in both Canada and the US. He is a Venture Partner at Lumira Capital, a member of the Research Committee for CAMH, an Advisory BOD member for the Ivey International Centre for Health Innovation, and a Past-President and Director of the Osler Bluff Ski Club and Director of Alpine Ontario.


  • Steven Saviuk,
    Director

    Mr. Saviuk has an extensive background in finance and venture capital investing including a number of successful health science companies. He co founded Valeo Pharma in 2003 and has served as its President and CEO since its inception and has overseen its transformation from its early years as an in licensor of established brands to a fast growing full service Canadian pharmaceutical company.


  • Michael Buschmann,
    Director

    Mike is a Professor at Polytechnique Montréal since June 1994. Dr. Buschmann has a Ph.D. in Medical Engineering and Medical Physics from MIT and Harvard University, with postdoctoral training in cartilage repair and histology completed at the University of Bern in Switzerland. Since 1994 he has conducted a multidisciplinary research program at Polytechnique Montréal that focuses on the use of biomaterials to repair meniscus, rotator cuff and cartilage and to deliver mRNA and small interfering RNA using nanovectors.


  • Caroline Hoemann,
    Director

    Caroline Hoemann is a Professor at Polytechnique Montréal since October 2005 as well as a member of the Biomedical Science and Technologies Research Group (GRSTB). Dr. Hoemann has a M.Sc. in Applied Biology and a Ph.D. in Toxicology from MIT. She is a member of the Ordre des Ingénieurs du Québec since 2010, and was awarded Junior II, Senior, and National career fellowships from the Fonds de la Recherche Santé du Quebec (FRQ-S) for her research in biomaterial devices for articular cartilage repair.


  • Laurence Terrisse-Rulleau,
    Director

    Laurence Rulleau is a Principal at CTI Life Science Fund II since December 2014. From November 2011 to December 2014 she was V.P. Business Development at Gestion Univalor. From February 2008 to November 2011 she was CEO at HLA 6 Techno located in France. Mrs. Rulleau has a Master in Biology from the Université du Québec à Montréal and a Ph.D. in molecular biology from Université de Montréal.

Scientific Staff


  • Prof Michael Buschmann

    Mike is a Professor at Polytechnique Montréal since June 1994. Dr. Buschmann has a Ph.D. in Medical Engineering and Medical Physics from MIT and Harvard University, with postdoctoral training in cartilage repair and histology completed at the University of Bern in Switzerland. Since 1994 he has conducted a multidisciplinary research program at Polytechnique Montréal that focuses on the use of biomaterials to repair meniscus, rotator cuff and cartilage and to deliver mRNA and small interfering RNA using nanovectors.


  • Prof Caroline Hoemann

    Caroline Hoemann is a Professor at Polytechnique Montréal since October 2005 as well as a member of the Biomedical Science and Technologies Research Group (GRSTB). Dr. Hoemann has a M.Sc. in Applied Biology and a Ph.D. in Toxicology from MIT. She is a member of the Ordre des Ingénieurs du Québec since 2010, and was awarded Junior II, Senior, and National career fellowships from the Fonds de la Recherche Santé du Quebec (FRQ-S) for her research in biomaterial devices for articular cartilage repair.

Clinical Advisory Board


  • Dr. Scott Rodeo

    Dr. Scott Rodeo is Professor of orthopedic Surgery at Weill Medical College of Cornell University and is an Attending Surgeon at the New York-Presbyterian Hospital and the Hospital for Special Surgery, where he is Co-Chief Emeritus of the Sports Medicine and Shoulder Service and Co-Director of the Tissue Engineering, Regeneration and Repair Program.

    He is Head Team Physician for the New York Giants Football Team. Rodeo served as a Team Physician for the United States Olympic Team in 2004, 2008, and 2012. His clinical practice involves orthopedic sports medicine, with specialty interest in complex knee reconstruction (ligament, meniscus and cartilage surgery), tendon repair in the shoulder and other joints, and shoulder instability. Rodeo graduated cum laude from Stanford University, where he completed his undergraduate work while competing on the Stanford Swimming Team. He completed medical school graduating with honors from Cornell University Medical College.


  • Dr Jack Farr

    Dr Jack Farr's orthopedic Focus includes knee restoration surgery, cartilage restoration, sports medicine and partial knee replacement.

    He attended Indiana University School of Medicine and completed his residency in orthopedic surgery at Indiana University School of Medicine. He is Board Certified by the American Board of orthopedic Surgeons, and is affiliated with the American Academy of orthopedic Surgeons, American orthopedic Society for Sports Medicine, International Cartilage Repair Society. His hospital affiliations include Indiana orthopedic Hospital, St. Vincent Hospital, Community Hospital South. He is also a voluntary Clinical Professor of orthopedic Surgery IU Medical Center; Director, OrthoIndy Sports Medicine Fellowship; Director, Cartilage Restoration of Center of Indiana and Vice President, Patellofemoral Foundation.


  • Dr Martyn Snow

    Dr Martyn Snow is a Consultant orthopedic Surgeon at The Royal orthopedic Hospital, UK.

    Professor Snow's interests include all aspects of shoulder surgery. In particular, arthroscopic procedures such as rotator cuff repair, shoulder stabilisations, capsular release for frozen shoulder and ACJ injuries. He also performs shoulder replacement for arthritis of the shoulder.

    He has a major interest in sporting injuries of the knee, including Anterior and Posterior Cruciate Ligament reconstruction. He treats all aspects of cartilage injuries in the young adult, using the full spectrum of cartilage regeneration techniques, osteotomy, unicondylar and total knee replacement.

    Professor Snow has over 30 publications in various International medical journals, has written 4 book chapters on knee and shoulder injuries and has presented over 50 papers at various national and International meetings.

    He very active in the research community and is currently chief investigator in a number on-going trials. His current areas of interest include, the use of stem cells in cartilage repair, improving tendon healing in rotator cuff repair and functional improvements following ACL reconstruction.

    He is a graduate of Edinburgh University and undertook his Registrar training in the Manchester region. He spent 18 months on fellowship in North America, 12 months in Halifax, Nova Scotia undertaking a Sports Medicine fellowship at the Sports Medicine Clinic of Nova Scotia. He subsequently spent 6 months at the Holand orthopedic and Arthritic Centre in Toronto, gaining further experience in Shoulder and Knee surgery. In 2006 he completed an MSc in orthopedic Engineering from Cardiff University. Professor Snow has since designed his own fixation device for use in ACL reconstruction, which is currently in use by orthopedic surgeons world wide.